Grünenthal has added another orphan disease drug to its pipeline to treat complex regional pain syndrome (CRPS) by acquiring US-based Thar Pharmaceuticals for an undisclosed amount. The lead candidate of the deal is an oral form zoledronic acid, T121, which is a Phase III ready orphan drug. With the acquisition, Grünenthal now has worldwide rights to T121 and Thar’s proprietary technology platform Enhance™ along with a few other early-stage programmes.